Articles On Impression Healthcare (ASX:IHL)

Incannex lodged extensive registration form with SEC. A strategic dual-listing will give Incannex access to larger pools of capital with investors who are experienced in psychedelics and medicinal cannabis. For Incannex Healthcare (ASX:IHL)...

Local pot stock Incannex Healthcare [ASX:IHL] is in traders’ sights today. The stock shares is currently up 4.36% and climbing. The post Incannex Healthcare Files for US IPO Sending the Shares 4% Higher (ASX:IHL) appeared first on Money Mor...

The Incannex Healthcare Ltd (ASX: IHL) share price is on the move in afternoon trade after the company gave a key update. Incannex shares are now exchanging hands at 29 cents apiece, a 5.4% gain after reaching a high of 30.5 cents this mo...

Clinical-stage pharmaceutical development company Incannex Healthcare (ASX: IHL) has filed a registration statement with the United States Securities and Exchange Commission (SEC) relating to a proposed initial public offering (IPO). The co...

Highlights Incannex Healthcare has filed a registration statement for a planned IPO (initial public offering), seeking to be listed on NASDAQ under the ‘IXHL’ ticker. Telix has commenced two new studies to assess the potential utility...

Massachusetts based cannabis operator MariMed has just announced a joint collaboration with the legendary Boston ice cream brand Emack & Bolio’s® to create a line-up of cannabis-infused vegan and dairy ice cream. The ice cream will cont...

The ASX200 health stocks index (XHJ) fell by 0.14% this morning, compared to the broader index which rose by 0.35%. Medical imaging specialist, EMVision (ASX:EMV), has rocketed by 16% after announcing that 1st Gen portable brain scanner has...

Clinical-stage pharmaceutical development company Incannex Healthcare (ASX: IHL) has completed a Human Research Ethics Committee submission for a phase 2a Psi-GAD study, which combines the administration of psilocybin (or magic mushroom-bas...

Wall Street mixed as oil and metals fall US stock markets were mixed on Monday, as oil prices fell to a three-week low on concerns about the virus spread in China and the rising US dollar. The Dow Jones fell by 0.3%, S&P 500 down by 0.0...

The Incannex Healthcare Ltd (ASX: IHL) share price has remained flat in this morning’s trade, without any excitement either way. Incannex shares haven’t budged despite the healthcare company providing an update on its progress for the qua...

Special Report: Along with Phase 1 trials for IHL-675A, the company also received a positive response with respect to its global patent application from the Patent Examiner. Incannex Healthcare (ASX:IHL) announced the latest key update for...

Clinical stage cannabinoid and psychedelic medicine development company Incannex Healthcare (ASX: IHL) has started a phase 1 clinical trial assessing a soft gel capsule formulation of its multi-use drug candidate IHL-675A in healthy volunte...

The Incannex Healthcare Ltd (ASX: IHL) share price stormed 5.45% higher to 29.5 cents after resuming trade this morning. In early afternoon, the share price has retreated to 28 cents, up 1.82% on its previous closing price. Shares in th...

IHL is on track to obtain clinical results from its Phase 2b trial in the second half of this year. Clinical stage cannabinoid and psychedelic medicine company, Incannex Healthcare (ASX:IHL), continues to execute with a run of positive deve...

Clinical stage cannabinoid and psychedelic development company Incannex Healthcare (ASX: IHL) has filed an international patent application as part of the development program for its drug IHL-42X for the treatment of obstructive sleep apnoe...

The ASX Healthcare index rose by 0.45% this morning, compared with the broader index which fell by 0.80%, helped by medicinal cannabis company AusCann (ASX:AC8). It rose by 5% in morning trading. AusCann announced it has submitted the first...

The Incannex Healthcare Ltd (ASX: IHL) share price won’t be going anywhere today.   Shares in the emerging pharmaceutical company were placed in a trading halt before markets opened. Here’s why. Incannex shares halted on patent update and...

The Incannex Healthcare [ASX:IHL] share price rose 5.5% in early trade after IHL engaged a firm to manufacture IHL-675A soft-gel capsules pending clinical trials. The post Incannex Share Price Up on IHL-675A Manufacture Update (ASX:IHL) app...

The Incannex Healthcare [ASX:IHL] share price rose 5.5% in early trade after IHL engaged a firm to manufacture IHL-675A soft-gel capsules pending clinical trials. The post Incannex Share Price Up on IHL-675A Manufacture Update (ASX:IHL) app...

Incannex has engaged Procaps to develop and manufacture its IHL-675A soft-gel capsules in preparation for clinical trials. The company’s anti-inflammatory multi-use drug product will be developed with Procaps’ ́proprietary patented Unigel t...

Wall Street mixed as F45 makes US IPO debut There was no clear direction in US equities markets overnight, and like the previous day, the benchmarks finished in mixed territories again. The Dow Jones finished 0.15% higher, S&P 500 was l...

Specialised pharmaceutical manufacturer Procaps SA has been engaged by Incannex Healthcare (ASX: IHL) to develop the specific formulation for its drug IHL-675A using Procaps’ Unigel capsule technology. Under the terms of the deal, Procaps w...

The company now has a targeted research pathway to clinical success, with strong proprietary protection as it moves towards commercialisation. As a market leader in the clinical development of cannabinoid and psychedelic based medical solut...

Summary The ASX 200 closed sharply lower by 133.60 points or 1.81% at 7,235.30. The market witnessed a sharp, heavy sell-off on persistent concerns over hawkish outlook by the US Federal Reserve. All four big four lenders - Westpac, C...

The deal gives IHL a global partner to develop the drug and navigate the global regulatory backdrop. Incannex Healthcare (ASX:IHL) flagged another key step forward this morning in the clinical development and manufacture of its IHL-216A tre...

Cannabinoid development company Incannex Healthcare (ASX: IHL) has announced it has engaged drug manufacturer Vectura Limited to develop the specific formulation required for clinical trials of IHL-216A, its lead drug for the treatment of t...

Wall Street plummets on ‘Triple Witching day’ All major US indices fell on Friday, mostly on inflation worries as investors are concerned about an earlier than expected increase in rates. St Louis Fed Reserve chairman James Bullard’s commen...

Last week the US government announced it would begin granting growing approvals to several companies for medicinal marijuana research, ending an informal moratorium on licence issuing which has been in place since the Trump administration....

The company has partnered with one of Australia’s leading sleep science research as the second test site for ongoing clinical trials.  Clinical-stage cannabis and psychedelics company Incannex Healthcare (ASX:IHL) has taken another importan...

Clinical stage pharmaceutical development company Incannex Healthcare (ASX: IHL) has engaged the University of Western Australia’s Centre for Sleep Science as an additional site for an ongoing trial investigating the effects of drug candida...

Tech stocks fell hard on the eve of US CPI report All major indices fell overnight on inflation fears, with tech and growth stocks the major losers. The US Labour Department will release its inflation report on Wednesday, US time. The Dow J...

In a historic first, a medicinal cannabis drug has been listed on Australia’s Pharmaceutical Benefits Scheme (PBS), enabling Australians living with Dravet syndrome access to treatment for the rare form of epilepsy. Federal health minister...

The Incannex share price was up 3.5%. The Incannex Healthcare Ltd [ASX:IHL] advanced its clinical trials in the December quarter while posting a cash balance of $10.4 million... The post Incannex Share Price Rises on Quarterly Report (ASX:...

Summary Neuren Pharmaceuticals obtained a Canadian patent grant for trofinetide, with a patent term that extends to January 2032. Health technology company Medibio Limited has secured a pre-submission meeting with the FDA for a new 510...

The company is moving from strength to strength as it builds out its drug development pathway for the lucrative US market. Pharmaceutical cannabis and psychedelic company Incannex Healthcare (ASX:IHL) is coming off a busy quarter as it exec...

Summary Oventus Medical witnessed growth in booked revenue and acceleration in telehealth bookings in Q3 FY21. ECS Botanics Holdings’ March 2021 quarter was action-packed with a major acquisition and multiple supply agreements. Despit...

The US cannabis market reacted in jubilation last week, after the Secure and Fair Enforcement (SAFE) Banking Act — which would make it legal for insurers and banks to work with the cannabis industry — was successfully passed by the House of...

Incannex provides investors the best of breed for medicinal cannabis and psychedelic therapy development – and they’re looking at an excursion to the USA For Incannex Healthcare (ASX:IHL) CEO Joel Latham, 2021 is shaping up as a big year a...

ASX pot stocks have run hot in recent months but eight in particular have been particularly rewarding for shareholders. Many pot stocks ran cold prior to COVID-19 as regulatory progress stalled and global markets didn’t take off. Australia...

April 20 has come and gone, but ASX cannabis companies aren’t getting that high — they’re actually low. Of the 36 pot companies in the space, 27 have lost ground over the last fortnight. Just seven have advanced. Gains were led by Wide Open...

The Incannex Healthcare Ltd (ASX: IHL) share price is in reverse during late-afternoon trade. This comes despite the company’s positive pre-investigational new drug application (pre-IND) meeting with the United States Food and Drug Adminis...

Pharmaceutical cannabis and psychedelic medicine company Incannex Healthcare (ASX:IHL) continues to execute on its multi-channel development pathway for clinically-proven cannabinoid treatments. And the company announced some more good news...

Clinical stage pharmaceutical development company Incannex Healthcare (ASX: IHL) has held a pre-investigational new drug application meeting with the US Food and Drug Administration (US FDA) to discuss the regulatory pathway for lead candid...

Summary Exopharm obtained firm commitments from institutional and sophisticated investors to raise a total of AU$12 million. Race Oncology announced that its new Chief Medical Officer, Dr David Fuller, is set to join on 1 July 2021....

The mere mention of magic mushrooms, ecstasy or ketamine is enough to send parents of teenagers into conniptions. But are these so-called party drugs poised to follow cannabis into the realm of a medical treatment within a legitimate listed...

Special Report: Incannex Healthcare (ASX:IHL) is making steady progress on its hydroxychloroquine (HCQ)/cannabidiol (CBD) drug combination and will be meeting with US regulators shortly on an approval pathway. The Melbourne-based pharmaceut...

The pharmaceutical development company, Incannex Healthcare Ltd [ASX:IHL] share price is up after announcing a pre-IND meeting with the US FDA. At 2:30pm today, the IHL share price was up 5%... The post Incannex Healthcare Share Price Up o...

The Incannex Healthcare Ltd (ASX: IHL) share price is climbing on the back of a positive update regarding its therapy, IHL-675A. At the time of writing, the healthcare company’s shares are up 5%, trading at 21 cents. What did Incannex anno...

Incannex Healthcare (ASX: IHL) will confer with the United States Food and Drug Administration after the body granted a pre-investigational new drug meeting regarding progressing the company’s IHL-675A drug in preventing acute respiratory d...

Cannabis stock Bod Australia (ASX:BDA) has entered the fight against what is known as “long-COVID”.   What is ‘long-COVID’? “Long-COVID” occurs when people suffer COVID-19 symptoms for several weeks of months after the initial onset of symp...